Phase 2 Trial of Tomivosertib Begins Dosing Advanced Castration-resistant PC Patients
News
A Phase 2 clinical trial evaluating eFFECTOR Therapeutics’ investigational therapy tomivosertib (eFT508), for men with advanced castrate-resistant prostate cancer (CRPC) who failed to respond to androgen receptor signaling (ARS) inhibitors, has begun ... Read more